Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire•04/11/2026•16:06 ET
2
Key Highlights
- ➤$528.5 million cash, securities expected to fund operations into 2H 2029
- ➤CLARITY-101 Phase 1/1b trial initiated after U.S. FDA IND clearance
- ➤DMR-001 showed average 95-fold potency improvement across 10 non-Type 1 mutations
- ➤Net loss widened to $32.0 million from $3.1 million year over year
- ➤DMR-002 first regulatory submission targeted for fourth quarter 2026
Expert Statements
Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics
“Since we initiated the CLARITY-101 trial of DMR-001, we have continued to execute with urgency, initiating enrollment at multiple clinical sites, achieving U.S. FDA clearance of our DMR-001 investigational new drug (IND) application and advancing multiple regulatory submissions to rapidly bring the CLARITY-101 trial to additional regions of the world”
Jennifer Jarrett, President and Chief Executive Officer of Damora Therapeutics
“In addition, we are excited to present new preclinical data at ASH that further strengthen DMR-001’s differentiated profile, including potentially best-in-class pan-mutant activity across the full range of CALR mutations. Together with our broader portfolio, including DMR-002 and DMR-003, Damora is exceptionally well positioned to address medical needs across the spectrum of patients with mutCALR-driven disease and become a leader in myeloproliferative neoplasms.”
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) --
-- New preclinical data highlighting DMR-001’s potentially best-in-class pan-mutant CALR (mutCALR) activity to be presented at the American Society of Hematology (ASH) 2026 Annual Meeting --
Get started
Create a free account to read the full story.